Cargando…

Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial

BACKGROUND/AIMS: Clarithromycin resistance is a main factor for treatment failure in the context of Helicobacter pylori infection. However, the treatment regimen for clarithromycin-resistant H. pylori infection has not yet been determined. We aimed to compare the efficacy and cost-effectiveness of 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Seung In, Lim, Hyun, Bang, Chang Seok, Yang, Young Joo, Baik, Gwang Ho, Lee, Sang Pyo, Jang, Hyun Joo, Kae, Sea Hyub, Kim, Jinseob, Kim, Hak Yang, Shin, Woon Geon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474493/ https://www.ncbi.nlm.nih.gov/pubmed/35145043 http://dx.doi.org/10.5009/gnl210365

Ejemplares similares

Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication
por: Yoon, Jai Hoon, et al.
Publicado: (2012)

Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency
por: Lee, Moon Won, et al.
Publicado: (2022)

Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial
por: Lim, Hyun, et al.
Publicado: (2018)

Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
por: Moon, Sang-Gon, et al.
Publicado: (2022)

The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication
por: Arj, Abbas, et al.
Publicado: (2020)

Intraluminal Therapy for Helicobacter pylori Infection—Comparison of Medicament Containing Tetracycline, Metronidazole, and Bismuth versus Amoxicillin, Metronidazole, and Clarithromycin: A Randomized Controlled Study
por: Liu, Ting-Wen, et al.
Publicado: (2023)

Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure
por: Fakheri, Hafez, et al.
Publicado: (2016)

Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea
por: Moon, Ji Yoon, et al.
Publicado: (2013)

Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017)

Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection
por: Lee, Gil Ho, et al.
Publicado: (2020)

Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
por: Lee, Ju Yup, et al.
Publicado: (2016)

Comparison of eradication rates of moxifloxacin–rifabutin triple therapy and bismuth quadruple therapy as second‐line regimens in patients with peptic ulcers
por: Lee, Chang Min, et al.
Publicado: (2022)

Outcomes of the Conventional versus Pocket-Creation Method for Endoscopic Submucosal Dissection of Gastric Body Tumors Using a Dual Knife: A Retrospective Study
por: Lee, Sang Pyo, et al.
Publicado: (2023)

A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance
por: Adachi, Kazunori, et al.
Publicado: (2023)

Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection
por: Kim, Jeemyoung, et al.
Publicado: (2022)

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)

Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections
por: Yang, Tiankuo, et al.
Publicado: (2020)

Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial
por: Su, Jing, et al.
Publicado: (2017)

Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial
por: Kim, Young-Il, et al.
Publicado: (2021)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

Comparison of Azithromycin and Metronidazole in a Quadruple-Therapy Regimen for Helicobacter pylori Eradication in Dyspepsia
por: Agah, Shahram, et al.
Publicado: (2009)

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
por: Jheng, Guang-Hong, et al.
Publicado: (2015)

Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
por: Niu, Zhan-Yue, et al.
Publicado: (2021)

Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn’s Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review
por: Jung, Eun Suk, et al.
Publicado: (2021)

Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study
por: Kim, Ji Yoon, et al.
Publicado: (2023)

Indication, Location of the Lesion, Diagnostic Yield, and Therapeutic Yield of Double-Balloon Enteroscopy: Seventeen Years of Experience
por: Lee, Sang Pyo, et al.
Publicado: (2022)

Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy
por: Sun, Yingchao, et al.
Publicado: (2022)

Helicobacter pylori Eradication According to Sequencing-Based 23S Ribosomal RNA Point Mutation Associated with Clarithromycin Resistance
por: Seo, Seung In, et al.
Publicado: (2019)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy
por: Kim, Min Soo, et al.
Publicado: (2013)

Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial
por: Kim, So Jeong, et al.
Publicado: (2019)

Second-Line Bismuth-Containing Quadruple Therapy for Helicobacter pylori Infection: A 12-Year Study of Annual Eradication Rates
por: Shin, Kiwon, et al.
Publicado: (2021)

Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia
por: Alsohaibani, Fahad, et al.
Publicado: (2020)

Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
por: Zhang, Lingyun, et al.
Publicado: (2019)

The efficacy and safety of furazolidone-bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotic supplementation
por: Noorbakhsh, Nafeh, et al.
Publicado: (2022)

Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial
por: Mansour-Ghanaei, Fariborz, et al.
Publicado: (2019)

Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant Helicobacter pylori
por: Sue, Soichiro, et al.
Publicado: (2023)

Efficacy of Clarithromycin Containing Bismuth–Based Regimen as a Second-Line Therapy in Helicobacter Pylori Eradication
por: Mokhtare, Marjan, et al.
Publicado: (2015)

Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection
por: Lee, Seong tae, et al.
Publicado: (2015)

Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori
por: Seyyedmajidi, Mohamadreza, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dt45lcfcnim7gvb609ol221p7q